Blood Tests for Cancer: RGCC's Liquid Biopsy Tests for Personalized Cancer Care
RGCC’s blood tests for cancer analyze a simple blood sample using advanced liquid biopsy testing and genomic testing technologies to support early cancer detection, treatment personalization, and ongoing cancer monitoring. These cancer blood tests help identify circulating tumor cells (CTCs), cancer markers in the blood, and tumor-specific genetic characteristics associated with malignant tumors.
By delivering clinically actionable insights, RGCC tests empower clinicians to make data-driven decisions, supporting precision medicine oncology and fully personalized cancer care. This approach enhances treatment accuracy, patient safety, and overall outcomes across the cancer care journey.
Precision Oncology: Benefits of Liquid Biopsy in Cancer Care
Using advanced molecular diagnostics and precision oncology testing, our cancer diagnostics support personalized treatment decisions that move beyond a one-size-fits-all approach. By analyzing tumor-specific and genetic characteristics, our cancer tests enable clinicians to design individualized cancer treatment plans tailored to each patient’s unique disease profile.
Our range of cancer tests supports the principles of precision medicine in oncology by refining treatment strategies, improving therapeutic precision, and prioritizing patient safety, ultimately leading to better patient outcomes.
RGCC cancer tests are based on non-invasive liquid biopsy technologies, offering a safer and less stressful alternative to traditional diagnostic methods such as tissue biopsies. In most cases, only a simple blood sample is required, eliminating the need for surgical intervention or tissue removal.
Circulating Tumor Cells Test
A circulating tumor cells test is a type of liquid biopsy cancer test that detects and analyzes key cancer-related components circulating in the bloodstream, including circulating tumor cells (CTCs), tumor markers, and circulating tumor DNA (ctDNA). These insights support cancer detection, diagnosis, and continuous monitoring of disease progression over time.
Circulating tumor cells are cancer cells that have detached from a primary cancerous tumor and entered the bloodstream or lymphatic system, where they may contribute to the development of secondary tumors or metastasis.
A circulating tumor cells test provides valuable insights into tumor behavior, disease aggressiveness, and potential spread.
This information can help guide personalized treatment decisions, monitor tumor evolution, and assess response to therapy over time.
What Info do RGCC Cancer Blood Tests Provide?
RGCC cancer tests are designed to deliver clinically relevant results across the full cancer care journey, including:
Cancer risk assessment and early detection
of potential, previously unrecognized cancers through the identification of cancer markers in the blood
Monitoring
of existing, diagnosed cancers
Follow-up testing
to assess treatment response and disease progression
Personalized treatment insights
including sensitivity to conventional drugs and supportive natural therapies
Are you interested in a blood test for early cancer diagnosis, disease analysis or therapy monitoring? Feel free to contact us!
Our Onconomics panels assess the genetic and genomic profile and employ a dual approach, combining molecular and cellular methods to determine sensitivity to specific treatment options, including chemotherapy, targeted therapies, and supportive natural compounds. This approach enables more precise and effective cancer treatment planning while prioritizing patient safety.
By narrowing down treatment options to those most likely to be effective, RGCC testing provides clinicians with data-driven insights that enhance treatment precision and offer patients better chances for successful outcomes.
Cancer Screening Test for Multi-Cancer Early Detection
Early detection plays a critical role in improving cancer outcomes. RGCC’s multi-cancer early detection test, Onco-D-Clare, is a liquid biopsy cancer screening tool designed to detect cancer based on each person’s genetic profile at the earliest stages, even before symptoms appear.
This advanced cancer test supports proactive monitoring and early intervention for more effective disease management.
RGCC testing supports clinicians and patients at every stage of care.
RGCC offers a comprehensive portfolio of cancer blood tests tailored to different clinical scenarios, from early cancer screening to advanced treatment planning and long-term monitoring.
Explore our liquid biopsy portfolio to find the RGCC solution best aligned with your clinical objectives and personalized cancer care goals. Learn more about RGCC’s research and development here.
Onconomics Extracts+ provides highly detailed and accurate information about how effective specific natural substances and plant extracts are. Furthermore,…
Explore the convenience of our doctor's portal, where you can effortlessly order kit vials, monitor your patients' test results, and access a comprehensive array of resources and tutorials. With these tools at your fingertips, you can confidently make informed decisions for personalized patient care.
Not yet part of the RGCC network? Join our community of doctors and medical practitioners today.
Explore the Scientific Advancements behind RGCC Technologies
Our dedicated scientific team drives continuous innovation in cancer research, molecular diagnostics, and precision medicine. Through ongoing clinical trials and advanced laboratory research, RGCC develops cutting-edge technologies that support personalized cancer management.
Discover our latest publications & scientific articles to stay informed about emerging insights, validated methodologies, and breakthroughs shaping the future of oncology research.
